Associate Professor, Medicine-Massachusetts General Hospital, Harvard Medical School
Hematology
Dr. Richard T. Penson, MD
|
|
Give Review
Richard T. Penson practices Hematology. He has 2 awards "Regional Top Doctor" and "Meaningful Use Stage 1 Certification". Dr. Richard T. Penson is a published doctor. He has 101 publications published. The most current publication "Ovarian cancer: an update on genetics and therapy." He is registered with Medicare and accepts Medicare payments.
Publications
- Bevacizumab for advanced cervical Cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240).
- Primary debulking surgery for advanced ovarian Cancer: Are you a believer or a dissenter?
- A phase II study of ramucirumab (IMC-1121B) in the treatment of persistent or recurrent epithelial ovarian, Fallopian tube or primary peritoneal carcinoma.
- Recommended patient-reported core set of symptoms and quality-of-life domains to measure in ovarian Cancer treatment trials.
- Caring for One of Our Own.
- Vintafolide (EC145) for the treatment of folate-receptor-α positive platinum-resistant ovarian Cancer.
- Improved survival with bevacizumab in advanced cervical Cancer.
- Ascites Analysis by a microfluidic chip allows tumor-cell profiling.
- Phase 2 trial of aromatase inhibition with letrozole in patients with uterine leiomyosarcomas expressing estrogen and/or progesterone receptors.
- Ovarian Cancer, version 2.2013.
- PRECEDENT: A Randomized Phase II Trial Comparing Vintafolide (EC145) and Pegylated Liposomal Doxorubicin (PLD) in Combination Versus PLD Alone in Patients With Platinu...
- Clear cell Cancer of the ovary.
- Case records of the Massachusetts General Hospital. Case 14-2013. A 70-year-old woman with vaginal bleeding.
- A phase II trial of Sunitinib malate in recurrent and refractory ovarian, Fallopian tube and peritoneal carcinoma.
- Phase II Activity of Belinostat (PXD-101), Carboplatin, and Paclitaxel in Women With Previously Treated Ovarian Cancer.
- Safety, Efficacy, and Biomarker Exploration in a Phase II Study of Bevacizumab, Oxaliplatin, and Gemcitabine in Recurrent Müllerian Carcinoma.
- A phase II, single-arm study of the anti-α5β1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial Ovarian or primary p...
- Epithelial ovarian Cancer.
- Acupuncture as palliative therapy for physical symptoms and quality of life for advanced Cancer patients.
- Case records of the Massachusetts General Hospital. Case 8-2010. A 22-year-old woman with hypercalcemia and a pelvic mass.
- Rapid development of hypertension and proteinuria with cediranib, an Oral vascular endothelial growth factor receptor inhibitor.
- Phase II trial of GM-CSF in women with asymptomatic recurrent müllerian Tumors.
- Connection: Schwartz Center Rounds at Massachusetts General Hospital Cancer Center.
- Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian Tumors.
- Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, Fallopian tube, and peritoneal ...
- Comparison of the quality of life of early and advanced stage ovarian Cancer survivors.
- Acupuncture for chemotherapy-induced Neutropenia in patients with gynecologic malignancies: a pilot randomized, sham-controlled clinical trial.
- Risk stratification for desensitization of patients with carboplatin hypersensitivity: clinical presentation and management.
- Ovarian stromal and germ Cell tumors.
- Sugar fuels Cancer.
- Phase II prospective study of paclitaxel and carboplatin in older patients with newly diagnosed Müllerian Tumors.
- Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian Cancer.
- Cycles within cycles.
- Phase II study of bevacizumab in patients with platinum-resistant ovarian Cancer or peritoneal serous Cancer.
- Hope.
- Teams: communication in multidisciplinary care.
- A phase II study of irofulven in women with recurrent and heavily pretreated ovarian Cancer.
- Direct-to-consumer advertising in oncology.
- Topotecan: weighing in when there are many options.
- Laughter: the best medicine?
- Learning to cope: how far is too close?
- Morphine analgesia in Cancer pain: role of the glucuronides.
- Fear of death.
- Cone damage in patients receiving high-dose irofulven treatment.
- Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 37-2004. A 52-year-old woman with postmenopausal bleeding and a cystic o...
- A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous Cancer, or fallopian tube Cancer.
- Silence as the speech of care.
- Detection of residual subclinical Ovarian carcinoma after completion of adjuvant chemotherapy.
- Expression of multidrug resistance-1 protein inversely correlates with paclitaxel response and survival in ovarian Cancer patients: a study in serial samples.
- Cancer as metaphor.
- Too old to care?
- Help me help you: support groups in Cancer therapy.
- Phase II study of liposomal doxorubicin and weekly paclitaxel for recurrent Müllerian Tumors.
- Overexpression of MAGE/GAGE genes in paclitaxel/doxorubicin-resistant human Cancer cell lines.
- Breaking bad news: a patient's perspective.
- Trust violated: Analgesics for addicts.
- Living as a Cancer surpriser: a doctor tells his story.
- The Kenneth B. Schwartz Center at Massachusetts General Hospital hematology-oncology department: hope for the homeless.
- Faith, identity, and leukemia: when blood products are not an option.
- When does the responsibility of our care end: bereavement.
- Virtual connections: Internet health care.
- Between parent and child: negotiating Cancer treatment in adolescents.
- Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian Cancer: a proof-of-concept trial.
- Long-term adjustment of survivors of ovarian Cancer treated for advanced-stage disease.
- Quality of life considerations in gynecologic Cancer. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer.
- Epithelioid angiosarcoma of the uterus: a review of management.
- Psychosocial issues in adolescents with Cancer.
- Phase I trial of escalating doses of topotecan in combination with a fixed dose of pegylated liposomal doxorubicin in women with müllerian malignancies.
- beta tubulin mutations are rare in human Ovarian carcinoma.
- The bioavailability and pharmacokinetics of subcutaneous, nebulized and Oral morphine-6-glucuronide.
- Overexpression of IL-6 but not IL-8 increases paclitaxel resistance of U-2OS human osteosarcoma Cells.
- Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation.
- Overexpression of human phosphoglycerate kinase 1 (PGK1) induces a multidrug resistance phenotype.
- Faith and freedom: leukemia in Jehovah Witness minors.
- Attitudes to chemotherapy in patients with ovarian Cancer.
- A phase II study of fixed dose rate gemcitabine in patients with relapsed müllerian Tumors.
- A phase I clinical trial of continual alternating etoposide and topotecan in refractory solid tumours.
- Combination chemotherapy with epirubicin, cisplatin and 5-fluorouracil for the palliation of advanced gastric and oEsophageal adenocarcinoma.
- Phantom pancreatic tumours.
- Ethical issues in Cancer treatment.
- Commentary: octreotide and hypertrophic pulmonary osteoarthropathy.
- Poor recruitment to lung Cancer trials.
- Double modulation of 5-fluorouracil with interferon alpha-2a and high-dose leucovorin in advanced Neuroendocrine tumours.
- A staff dialogue on aggressive palliative treatment demanded by a terminally ill patient: psychosocial issues faced by patients, their families, and caregivers.
- A staff dialogue on caring for a Cancer patient who commits suicide: psychosocial issues faced by patients, their families, and caregivers.
- Ovarian Cancer: an update on genetics and therapy.
- A staff dialogue on do not resuscitate orders: psychosocial issues faced by patients, their families, and caregivers.
- Progress in gynecologic oncology.
- Clinical course of stage IV epithelial ovarian Cancer.
- A staff dialogue on a socially distanced patient: psychosocial issues faced by patients, their families, and caregivers.
- Discovery of differentially expressed genes associated with paclitaxel resistance using cDNA array technology: Analysis of interleukin (IL) 6, IL-8, and monocyte chemo...
- Reality testing in Cancer treatment: the phase I trial of endostatin.
- Sedation for intractable distress of a dying patient: acute palliative care and the principle of double effect.
- Communicating genetic risk: pros, cons, and counsel.
- Sexuality and Cancer: conversation comfort zone.
- Burnout: caring for the caregivers.
- Medical mistakes: a workshop on personal perspectives.
- A phase II study of combined intravenous and subcutaneous interleukin-2 in malignant pleural mesothelioma.
- Randomized placebo-controlled trial of the activity of the morphine glucuronides.
- Olaparib monotherapy in patients with advanced relapsed ovarian Cancer and a germline BRCA1/2 mutation: a multi-study analysis of response rates and safety.
Schools
St Bartholomew39s Hospmedcollegeuniv Of London
Procedures Preformed
- Cardiac MRI (Magnetic Resonance Imaging) of Heart or Chest
- Thoracentesis
Conditions Treated
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- Bladder Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
- Hematology
Accepted Insurances
Awards
- Regional Top Doctor
- Meaningful Use Stage 1 Certification
Hospital
-
Brigham and Women's Hospital -
Newton-Wellesley Hospital -
Massachusetts General Hospital
Drug Facts
| NPI NUMBER | 1447240999 | |
| NPPES Provider LastName | PENSON | |
| NPPES Provider FirstName | RICHARD | |
| NPPES Provider ZIPCode | 021142621 | |
| NPPES Provider State | MA | |
| Specialty Description | Hematology | |
| Total Claim Count | 273.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 16.0 | |
| Percent Opioid Claims | 5.86 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1447240999 |
| Last Name Of The Provider | PENSON |
| First Name Of The Provider | RICHARD |
| View All |
Similar Doctors
|
|
Dr. Priscilla K. Brastianos, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jeffrey A. Barnes, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Matthew Smith, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mandar D. Muzumdar, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Paula G. Fraenkel, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Andrea C. Phelps, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Donald W. Kufe, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Richard A. Robinson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jeffrey A. Meyerhardt, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Philip J. Saylor, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Peter C. Yang, MD |
|
|
Dr. Gabriela Motyckova, MD
This Doctor is OpenDoctor Recommended.
|